Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|November 13, 2013
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteersAhmed A Othman, George Haig, Hana Florian, et al.
British Journal of Clinical Pharmacology|September 29, 2012
Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteersAhmed A Othman, George Haig, Hana Florian, et al.
The Journal of Rheumatology|February 19, 2008
A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgiaPhilip J Mease, I Jon Russell, Lesley M Arnold, et al.
Journal of Alzheimer'S Disease : JAD|March 12, 2016
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled StudyHana Florian, Andreas Meier, Serge Gauthier, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 24, 2025
Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's diseaseDeli Wang, Hana Florian, Shau-Yu Lynch, et al.
Clinical and Translational Science|January 10, 2026
Safety, Tolerability, and Pharmacokinetics of Single Doses of ABBV-916, an Anti-Amyloid Antibody, in Healthy ParticipantsSagar S Bachhav, Hana Florian, Joey Boiser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentShau Yu Lynch, Yamin Wang, Deli Wang, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 12, 2025
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meetingRonald C Petersen, Ana Graf, Chris Brady, et al.
Brain : a Journal of Neurology|February 2, 2023
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind studyHana Florian, Deli Wang, Steven E Arnold, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 29, 2023
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerationsRonald C Petersen, Ana Graf, Chris Brady, et al.
Pageof 2